Literature DB >> 22076573

Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung.

Joon Suk Park1, Yongjik Lee, Joungho Han, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Kwhanmien Kim.   

Abstract

OBJECTIVES: Sarcomatoid carcinoma of the lung is a very rare and aggressive subtype of non-small cell lung cancer. We explored the clinicopathologic characteristics and surgical outcome of this tumor.
METHODS: Among 4,212 patients who underwent curative resection for non-small cell lung cancer from September 1994 to December 2009, 99 patients had sarcomatoid carcinoma. Medical records of patients were reviewed retrospectively.
RESULTS: The mean follow-up period was 16.07 months. Thirty-six patients had pathologic stage I disease, and 63 had more advanced disease. Surgery included 2 wedge resections, 67 lobectomies, 17 bilobectomies, and 13 pneumonectomies. There were 90 pleomorphic carcinomas, 6 spindle cell carcinomas, 1 giant cell carcinoma, 1 carcinosarcoma, and 1 pulmonary blastoma. Overall 5-year survival was 54.3%. Forty-three patients experienced recurrence and 42 of these died of the cancer. Pathologic T stage as defined by the 7th TNM staging system was significantly associated with survival and recurrence (p = 0.004 and 0.002, respectively). Mean positron emission tomography uptake was significantly higher than in other types of lung cancer (p < 0.0001).
CONCLUSIONS: Our results implied that surgery for sarcomatoid carcinoma must be carefully planned after extensive preoperative evaluation. Efforts should be made for accurate preoperative histological diagnosis of large peripheral tumor with exceedingly high positron emission tomography uptake.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 22076573     DOI: 10.1159/000333095

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  29 in total

1.  Successful treatment of two consecutive cases of pulmonary pleomorphic carcinoma with platinum chemotherapy.

Authors:  Daisuke Kato; Yuichi Chihara; Tomoyuki Shirase; Tamaki Takahashi; Ken-Ichi Takahashi; Naoki Sakai
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

2.  Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report.

Authors:  Fangwen Zou; Guiyuan Xie; Jin-An Ma; Dong-Ai Zhou; Y I Jiang; Jiao-Yun Zheng
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

3.  Pulmonary carcinosarcoma successfully resected using the rib-cross thoracotomy approach: report of a case.

Authors:  Noriaki Sakakura; Tatsuo Uchida; Yuka Kitamura; Motokazu Suyama
Journal:  Surg Today       Date:  2012-10-12       Impact factor: 2.549

4.  Perioperative change in neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor in patients with completely resected primary pulmonary sarcomatoid carcinoma.

Authors:  Yong Won Seong; Sung Joon Han; Woohyun Jung; Jae Hyun Jeon; Sukki Cho; Sanghoon Jheon; Kwhanmien Kim
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

5.  Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy.

Authors:  Tomohiro Akaba; Yuno Shiota; Fumi Onizawa; Tamami Isaka; Yoji Nagashima; Etsuko Tagaya
Journal:  Respirol Case Rep       Date:  2021-05-07

Review 6.  Evaluation of six patients with pulmonary carcinosarcoma with a literature review.

Authors:  Sinem Nedime Sökücü; Celalettin Kocatürk; Nur Urer; Yaşar Sönmezoğlu; Levent Dalar; Levent Karasulu; Sedat Altın; Mehmet Ali Bedirhan
Journal:  ScientificWorldJournal       Date:  2012-04-24

7.  Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma.

Authors:  Kazuya Takeda; Haruo Matsushita; Masaki Kubozono; Takaya Tanabe; Yojiro Ishikawa; Takaya Yamamoto; Maiko Kozumi; Noriyoshi Takahashi; Yu Katagiri; Shun Tasaka; Katsuya Fukui; Ken Takeda; Fumiyoshi Fujishima; Masakazu Ichinose; Keiichi Jingu
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

8.  Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.

Authors:  Nagla Abdel Karim; James Schuster; Ihab Eldessouki; Ola Gaber; Tariq Namad; Jiang Wang; Changchun Xie; John C Morris
Journal:  Oncotarget       Date:  2017-12-18

9.  Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases.

Authors:  Si-Yuan Huang; Shu-Jing Shen; Xing-Ya Li
Journal:  World J Surg Oncol       Date:  2013-10-02       Impact factor: 2.754

10.  Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma.

Authors:  Jiewei Chen; Yongbo Xiao; Xiaoyan Cai; Jun Liu; Keming Chen; Xinke Zhang
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.